How the Tariff Shock Is Reshaping Markets To say that the weeks following the Trump administration's announcement of massive ...

Preclinical data further support the potential of dual-antigen and TGF-β-directed vaccines to reshape the tumor microenvironment and drive anti-tumor immunity NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) ...

The burden of babesiosis disease was significantly worse among patients with vs without immunocompromising conditions.

Amtagvi® and its accompanying design marks, Proleukin ®, Iovance ®, and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other ...

Partnered Assets: SIRPα antagonists BI 765063 and BI 770371, an improved next generation SIRPα inhibitor, developed in ...

In our weekly column, Quick Bites, we round up the latest developments in the alt-protein and sustainable food industry.

Piper Sandler analyst Allison Bratzel maintained a Buy rating on Scholar Rock Holding (SRRK – Research Report) today. The company’s shares ...

Dow Jones Industrial Average futures rose 506 points, or 1.3%. Futures tied to the S&P 500 popped 1.6%, while Nasdaq 100 ...

Older adults with cancer respond just as well as younger patients to immune checkpoint inhibitors despite age-related immune system differences, according to a new study.

Atreo, the next generation Randomization and Trial Supply Management (RTSM) provider, has released its groundbreaking v2.0 Platform. Specifically designed in collaboration with large pharmaceutical ...

Shares of Iovance Biotherapeutics have plummeted post-Amtagvi approval. Read more to see a full investment analysis for IOVA ...